Pacific Biosciences of California, Inc.

NasdaqGS:PACB 주식 보고서

시가총액: US$603.9m

Pacific Biosciences of California 미래 성장

Future 기준 확인 1/6

Pacific Biosciences of California (는) 각각 연간 33.4% 및 19.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 35.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -33.7% 로 예상됩니다.

주요 정보

33.4%

수익 성장률

35.6%

EPS 성장률

Life Sciences 수익 성장18.8%
매출 성장률19.5%
향후 자기자본 수익률-33.7%
애널리스트 커버리지

Good

마지막 업데이트12 Nov 2024

최근 미래 성장 업데이트

Recent updates

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

수익 및 매출 성장 예측

NasdaqGS:PACB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026258-169-86N/A12
12/31/2025193-202-122N/A14
12/31/2024157-359-250N/A14
9/30/2024173-394N/AN/AN/A
6/30/2024189-400-261-253N/A
3/31/2024200-297-249-240N/A
12/31/2023201-307-268-259N/A
9/30/2023170-309-274-262N/A
6/30/2023146-319-275-260N/A
3/31/2023134-321-296-279N/A
12/31/2022128-314-280-263N/A
9/30/2022137-299-249-234N/A
6/30/2022140-206-224-212N/A
3/31/2022135-175-176-167N/A
12/31/2021131-181-117-111N/A
9/30/2021122-37-97-94N/A
6/30/2021106-77-73-71N/A
3/31/202192-59-80-79N/A
12/31/202079291820N/A
9/30/202080-461416N/A
6/30/202083-511516N/A
3/31/202090-532122N/A
12/31/201991-84-81-78N/A
9/30/201982-115-82-79N/A
6/30/201979-111-78-76N/A
3/31/201976-109-76-73N/A
12/31/201879-103-68-66N/A
9/30/201884-93-71-68N/A
6/30/201889-90N/A-71N/A
3/31/201888-93N/A-70N/A
12/31/201793-92N/A-68N/A
9/30/201794-90N/A-60N/A
6/30/201796-86N/A-58N/A
3/31/201797-79N/A-64N/A
12/31/201691-74N/A-68N/A
9/30/2016101-57N/A-56N/A
6/30/201690-37N/A-56N/A
3/31/201694-31N/A-44N/A
12/31/201593-32N/A-48N/A
9/30/201573-49N/A-63N/A
6/30/201580-60N/A-53N/A
3/31/201567-67N/A-59N/A
12/31/201461-66N/A-51N/A
9/30/201453-64N/A-51N/A
6/30/201440-76N/A-26N/A
3/31/201434-77N/A-29N/A
12/31/201328-79N/A-30N/A

애널리스트 미래 성장 예측

수입 대 저축률: PACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PACB 의 수익(연간 19.5% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: PACB 의 수익(연간 19.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PACB (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y